José Baselga, MD, PhD
Frontline maintenance therapy with olaparib (Lynparza) significantly reduced the risk of disease progression or death versus placebo in patients with germline BRCA
m) metastatic adenocarcinoma of the pancreas, according to findings from the phase III POLO trial announced by AstraZeneca and Merck (MSD), the codevelopers of the PARP inhibitor.1
Beyond the improvement in progression-free survival (PFS), the companies also reported that there were no new safety signals with olaparib. AstraZeneca and Merck plan to report the specific data from the trial at a future medical meeting.
... to read the full story